NICE recommends aromatase inhibitors for early breast cancerBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7553.1292-d (Published 01 June 2006) Cite this as: BMJ 2006;332:1292
- Susan Mayor
Aromatase inhibitors are recommended as alternative options to tamoxifen for treating early breast cancer that is oestrogen receptor positive in postmenopausal women, says draft guidance for the NHS published this week.
The National Institute for Health and Clinical Excellence (NICE) advises on the use of treatments by the NHS in England and Wales. It recommended that the choice of treatment for oestrogen receptor positive breast cancer should be made after discussion between the patient and their doctor about the risks and benefits of the options available.
The options are primary adjuvant treatment with an aromatase …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial